Literature DB >> 7059263

Massive pleural effusions from prostatic lymphangitic carcinomatosis: resolution with endocrine therapy.

J E Heffner, D J Duffey, M I Schwarz.   

Abstract

Pleural effusions are a rare complication of metastatic adenocarcinoma of the prostate and have not been noted to resolve with endocrine therapy. In a patient with massive bilateral pleural effusions as the initial manifestation of underlying prostatic cancer, lung biopsy specimens documented the presence of lymphangitic carcinomatosis and pleural biopsy tissue was normal. The effusions cleared on two occasions after diethylstilbestrol diproprionate therapy was started. We conclude that massive pleural effusions occasionally complicate prostatic lymphangitic carcinomatosis and that they may resolve with endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059263

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Lobar collapse due to endobronchial metastatic prostatic carcinoma: re-expansion with antiandrogen treatment.

Authors:  H Taylor; S Braude
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

2.  Prostatic carcinoma presenting with respiratory symptoms: response to orchidectomy.

Authors:  F G Simpson; H A King; P Whelan; N J Cooke
Journal:  Thorax       Date:  1984-07       Impact factor: 9.139

3.  Malignant Ascites Associated with Carcinoma of the Prostate.

Authors:  Muhammad Wasif Saif
Journal:  J Appl Res       Date:  2005-01-01

4.  Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.

Authors:  Ji-Youn Youn; Andrew Nguyen; Hua Cai
Journal:  Clin Sci (Lond)       Date:  2012-10       Impact factor: 6.124

5.  Lymphangitic pulmonary metastases in castrate-resistant prostate adenocarcinoma.

Authors:  Andrew Meyer; Rachel Angelica Mariani; Chadi Nabhan
Journal:  Case Rep Med       Date:  2012-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.